227 related articles for article (PubMed ID: 35596146)
1. Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.
Liu W; Xie Y; Li Y; Zheng L; Xiao Q; Zhou X; Li Q; Yang N; Zuo K; Xu T; Lu NH; Zhang H
BMC Gastroenterol; 2022 May; 22(1):255. PubMed ID: 35596146
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.
Ha NY; Kim JW; Kim J
BMC Complement Med Ther; 2023 Dec; 23(1):444. PubMed ID: 38062418
[TBL] [Abstract][Full Text] [Related]
3. The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial.
Singh G; Haileselassie Y; Briscoe L; Bai L; Patel A; Sanjines E; Hendler S; Singh PK; Garud NR; Limketkai BN; Habtezion A
Clin Nutr ESPEN; 2022 Feb; 47():70-77. PubMed ID: 35063245
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: protocol for a pilot, randomized, double-blind, placebo-controlled trial.
Bhang YH; Kim KI; Kim J; Ahn J; Jung HS; Yang C; Ko SJ; Bu Y; Park JW; Park KS; Jung HJ; Lee JH; Lee BJ
Trials; 2020 Jan; 21(1):118. PubMed ID: 31996267
[TBL] [Abstract][Full Text] [Related]
10. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial.
Sun QH; Wang HY; Sun SD; Zhang X; Zhang H
World J Gastroenterol; 2019 May; 25(17):2110-2121. PubMed ID: 31114137
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
Tominaga K; Kato M; Takeda H; Shimoyama Y; Umegaki E; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Kusano M; Fujimoto K; Arakawa T;
J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
[TBL] [Abstract][Full Text] [Related]
14. Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial.
Shih YS; Tsai CH; Li TC; Yu CJ; Chou JW; Feng CL; Wang KT; Lai HC; Hsieh CL
Phytomedicine; 2019 Mar; 56():118-125. PubMed ID: 30668332
[TBL] [Abstract][Full Text] [Related]
15. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
Hussain S; Kierkus J; Hu P; Hoffman D; Lekich R; Sloan S; Treem W
J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):226-36. PubMed ID: 24121146
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
[TBL] [Abstract][Full Text] [Related]
18. Traditional Chinese medicine based on Tongjiang methodology combined with proton pump inhibitor (PPI) step-down in treating non-erosive reflux disease: a study protocol for a multicentered, randomized controlled clinical trial.
Li X; Wu H; Zhang B; Chen T; Shi X; Ma J; Zhang J; Tang X; Wang F
Trials; 2022 Oct; 23(1):879. PubMed ID: 36258217
[TBL] [Abstract][Full Text] [Related]
19. Effects of
Liu W; Lu NH; Zhou X; Li Y; Xie Y; Zheng L; Zhu W; Xiao Q; Yang N; Zuo K; Wu Q; Xu T; Zhang H
Evid Based Complement Alternat Med; 2022; 2022():4144321. PubMed ID: 35733625
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
